LATEST NEWS
September 3, 2025: ‘Radiance Biopharma signs exclusive license For ‘First In Class’ c-Met/EGFR targeted Nano Antibody ADC‘ – GlobeNewswire
More……
September 2, 2025: ‘Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC‘ – FIERCE Biotech
More……
April 15, 2025: ‘Radiance announces first patient dosing in Phase I Clinical Trial of its next generation ROR-1 targeted ADC for hematologic and solid malignancies‘ – GlobeNewswire
More……
April 1, 2025: ‘Radiance announces FDA clearance of IND application for a Phase I Clinical Trial of RB-164™, an ROR-1 targeted ADC, for hematologic and solid malignancies‘ – GlobeNewswire
More……
February 19, 2025: ‘Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner‘ – Fierce BIOTECH
More……
February 19, 2025: ‘Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate‘ – GlobeNewswire
More……
January 8, 2024: ‘Biocytogen enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma‘ – Businesswire
More……
Radiance Biopharma’s mission is to develop a pipeline of next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer and other high unmet medical needs.
Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.
RB-601™ is a ‘First-in-Man’ Nano Antibody Drug Conjugate targeting tumors expressing c-MET and EGFR. Learn more
RB-164™ is a ‘First-in-class’ ADC targeting ROR-1 which uses proprietary conjugation/linker technologies and the monomethyl auristatin E payload. Learn more
RB-201™ is a ‘First-in-class’ fully human Bispecific ADC targeting both HER2 and TROP-2 conjugated to the monomethyl auristatin E payload. Learn more
RB-203™ is a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more